Journal List > Allergy Asthma Respir Dis > v.4(3) > 1059179

Jin, Yoon, Nam, Ahn, Park, and Chung: Comparison of IgE-binding components between 2 house dust mites in adult allergic patients

Abstract

Purpose

This study investigated the differences in the profile of IgE-binding components between Dermatophagoides pteronyssinus (Dp) and Dermatophagoides farina (Df) in respiratory allergic patients sensitized to Dp/Df.

Methods

Eighteen patients with respiratory allergic diseases having higher levels of serum specific IgE to Df compared to those to Dp (>twice) were enrolled. IgE-immunoblot analysis using Dp and Df extracts were used to compare the IgE binding components. Study subjects were classified into 2 groups according to the results of IgE-immunoblot analysis: 6 subjects having IgE-binding components to group 1 and 2 allergens (group B) and 12 subjects not having them (group A).

Results

Group A subjects were older (47.92±8.51 vs. 35.50±11.10, P=0.039) and males were dominant (75% vs. 0% P=0.009). IgE-immunoblot analysis demonstrated that all the group B subjects had IgE bindings to 2 major components, 14 and 25 kDa, while group A subjects had IgE bindings to high-molecular weight components ranging from 60–98 kDa. The enzyme-linked immunosorbent assay inhibition test showed a significant inhibition with additions of Df, not with Dp in group B subjects. Serum specific IgE levels to Dp and Df were significantly higher in group B than in group A, while its ratio (Df to Dp) was significantly higher in group A. No differences were noted in clinical parameters, total IgE, or eosinophil cationic protein levels.

Conclusion

Heterogeneity of IgE binding patterns to Dp and Df extracts was noted according to the ratio of serum specific IgE (Df/Dp).

Figures and Tables

Fig. 1

Comparisons of serum specific IgE binding components by IgE immunoblot using Dermatophagoides pteronyssinus (Dp) and Dermatophagoides farinae (Df). Group A, the subjects not having IgE-binding components to groups 1 and 2 allergens; group B, the subjects having IgE-binding components to groups 1 and 2 allergens; a, Using Dp extracts; b, Using Df extracts; PC, positive control which were derived from the results from the patients with higher serum specific IgE levels to both Dp and Df; NC, negative controls.

aard-4-199-g001
Fig. 2

IgE enzyme-linked immunosorbent assay inhibition tests with serial additions of Dp, Df in sera from group A (A) and group B (B) subjects. Dp, Dermatophagoides pteronyssinus; Df, Dermatophagoides farina.

aard-4-199-g002
Table 1

Clinical characteristics of group A subjects

aard-4-199-i001
Patient No. Age (yr)/sex Disease Total IgE (kU/L) Specific IgE to Dp (kU/L) Specific IgE to Df (kU/L) Ratio (Df/Dp) ECP (µg/L) TEC (/µL) ITX with HDM Food allergy
1 51/M AR, AC 1,942 2.07 51.5 24.8 38.7 300 (-) (-)
2 42/F AICU 84 0.55 14.8 26.9 NA 100 (-) (-)
3 52/M AD, AR, EB 3,594 0 17.4 51.18 NA 134 (-) (-)
4 56/F AERD, IgG3 sub class deficiency 369 0.49 10.3 21.02 15.6 300 (-) (-)
5 64/M CU 145 0 8.26 24.30 NA 0 (-) (-)
6 53/M AR 636 0.86 19.2 22.32 NA 200 (-) (-)
7 39/M AR, AC 227 0 12.8 37.65 NA 300 (-) OAS-fruit
8 53/F AR, BA 365 0.73 5.12 7.14 22.00 250 (-) (-)
9 38/M Eosinophilia 4,405 2.18 32.5 14.9 126.00 500 (-) (-)
10 39/M AR, AICU 851 1.09 10.8 9.91 33.20 100 (-) (-)
11 38/M AR, AC 421 0.46 8.78 19.09 38.70 400 (-) (-)
12 50/M AR, BA, AICU 509 0.35 8.64 24.68 27.4 431 (-) (-)

Group A, the subjects not having IgE-binding components to groups 1 and 2 allergens; Dp, Dermatophagoides pteronyssinus; Df, Dermatophagoides farina; ECP, eosinophil cationic protein; TEC, total eosinophil count; ITX, allergen immunotherapy; HDM, house dust mite; AR, allergic rhinitis; AC, allergic conjunctivitis; AICU, aspirin intolerant chronic urticaria; AD, atopic dermatitis; EB, eosinophilic bronchitis; AERD, Aspirin-exacerbated respiratory disease; CU, chronic urticaria; BA, bronchial asthma; OAS, oral allergic syndrome; NA, not available; (+), the subject who has the history of immunotherapy with house dust mites or food allergy; (-), the subject has the history of immunotherapy with house dust mites or food allergy.

Table 2

Clinical characteristics of group B subjects

aard-4-199-i002
Patient No. Age (yr)/sex Disease Total IgE (kU/L) Specific IgE to Dp (kU/L) Specific IgE to Df (kU/L) Ratio (Df/Dp) ECP (µg/L) TEC (/µL) ITX with HDM Food allergy
1 33/F AR, BA 619 4.42 87.5 19.8 NA 64 (-) (-)
2 53/F AD 613 29.8 60.4 2.03 20.4 90 (+) (-)
3 35/F AR, AD 346 25.7 67.1 2.61 18.0 250 (+) (-)
4 26/F AD > 5,000 26.8 101 3.77 22.60 500 (-) (-)
5 43/F AR, AC, BA 2916 33.7 > 100 2.97 28.7 400 (-) (-)
6 23/F AR, AD 327 4.86 29.8 6.13 77.6 64 (-) (-)

Group B, the subjects having IgE-binding components to groups 1 and 2 allergens; Dp, Dermatophagoides pteronyssinus; Df, Dermatophagoides farinae; ECP, eosinophil cationic protein; TEC, total eosinophil count; ITX, allergen immunotherapy; HDM, house dust mite; AR, allergic rhinitis; BA, bronchial asthma, NA, not available; AD, atopic dermatitis; AC, allergic conjunctivitis; (+), the subject who has the history of immunotherapy with house dust mites or food allergy; (-), the subject has the history of immunotherapy with house dust mites or food allergy.

Table 3

Comparison of clinical features between the 2 groups

aard-4-199-i003
Variable Total Group A (n = 12) Group B (n = 6) P-value
Age (yr) 43.78 ± 10.93 47.92 ± 8.51 35.50 ± 11.10 0.04
Sex
 Male:female 9:9 9:3 0:6 0.01
Phenotype
 Airway allergy:nonairway allergy 13:5 9:3 4:2 > 0.99
Total IgE (kU/L) 1,080.53 ± 1,314.50 1,129.00 ± 1,436.87 1,637.00 ± 1,919.38 0.57
Log (total IgE) 2.78 ± 0.48 2.76 ± 0.53 2.97 ± 0.50 0.44
Specific IgE to Dp (kU/L) 7.45 ± 12.03 0.732 ± 0.74 20.88 ± 12.88 < 0.01
Specific IgE to Df (kU/L) 32.11 ± 30.21 16.68 ± 13.13 74.47 ± 27.66 < 0.01
Ratio of specific IgE (Df/Dp) 17.84 ± 13.25 23.66 ± 11.81 6.22 ± 6.81 < 0.01
ECP (µG/L) 39.08 ± 31.95 43.09 ± 37.54 33.46 ± 25.00 0.46
TEC (/µL) 243.50 ± 158.62 251.25 ± 150.36 228.00 ± 188.09 0.54

Values are presented as mean±standard deviation.

Group A, the subjects not having IgE-binding components to groups 1 and 2 allergens; group B, the subjects having IgE-binding components to groups 1 and 2 allergens; Dp, Dermatophagoides pteronyssinus; Df, Dermatophagoides farinae; ECP, eosinophil cationic protein; TEC, total eosinophil count.

Notes

study was supported by a grant from the Korean Health Technology R&D Project funded by the Ministry of Health & Welfare, ROK (H14C2628).

References

1. Yoon YW, Lee MK, Park HS, Park SS, Hong CS. The skin test reactivity and the level of the total IgE in the allergic patients. Allergy. 1989; 9:385–398.
2. Ahu SD, Kim HJ. The allergen skin test and the effect of specific desensitising vaccination therapy in allergic rhinitis and bronchial asthma. Allergy. 1983; 3:159–167.
3. Kim JH, Choi SY, Lee IY, Lee YW, Yong TS, Kim CW, et al. Seasonal variation of house dust mite and its influence on the inhabitant health. Korean J Asthma Allergy Clin Immunol. 2006; 26:27–34.
4. Kim SD, Chung SJ, Lee WJ, Koo DW. A study for prick test reactivities to allergen, peripheral blood eosinophils, and serum IgE levels in patients with urticaria and atopic dermatitis in Chuncheon and the Northern Kangwon province. Korean J Dermatol. 2001; 39:300–308.
5. Lee BG, Sim WY, Lee MH, Haw CR. A study of allergen prick test reactivity and peripheral blood eosinophil and total serum IgE levels in patients with atopic dermatitis and urticaria. Korean J Dermatol. 1989; 27:502–511.
6. Jung YH, Hwang KH, Yang SI, Lee E, Kim KH, Kim MJ, et al. Changes of aeroallergen sensitization in children with asthma or allergic rhinitis from a tertiary referral hospital in Seoul over 10 years. Allergy Asthma Respir Dis. 2014; 2:97–102.
7. Hong CS. Sensitization of house dust mites in the allergic patients and mite ecology in their house dusts. Allergy. 1991; 11:457–465.
8. Heymann PW, Chapman MD, Platts-Mills TA. Antigen Der f I from the dust mite Dermatophagoides farinae: structural comparison with Der p I from Dermatophagoides pteronyssinus and epitope specificity of murine IgG and human IgE antibodies. J Immunol. 1986; 137:2841–2847.
9. Jeong KY, Lee JY, Son M, Yi MH, Yong TS, Shin JU, et al. Profiles of IgE sensitization to Der f 1, Der f 2, Der f 6, Der f 8, Der f 10, and Der f 20 in Korean house dust mite allergy patients. Allergy Asthma Immunol Res. 2015; 7:483–488.
10. Thomas WR, Smith WA, Hales BJ, Mills KL, O'Brien RM. Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol. 2002; 129:1–18.
11. Cho HJ, Kim JH, Choi GS, Kim JE, Ye YM, Park HS. Clinical features of patients with apple allergy and identification of IgE-binding components of apple. Korean J Asthma Allergy Clin Immunol. 2010; 30:116–122.
12. Kim CW, Kim YS, Moon JS, Choi SY, Hong CS. Immunoblot analysis of specific IgE and IgG responses to Dermatophagoides farinae according to allergen bronchial challenge test. Korean J Asthma Allergy Clin Immunol. 2004; 24:394–402.
13. Jeong KY, Park JW, Hong CS. House dust mite allergy in Korea: the most important inhalant allergen in current and future. Allergy Asthma Immunol Res. 2012; 4:313–325.
14. Van Dyken SJ, Garcia D, Porter P, Huang X, Quinlan PJ, Blanc PD, et al. Fungal chitin from asthma-associated home environments induces eosinophilic lung infiltration. J Immunol. 2011; 187:2261–2267.
15. Mack I, Hector A, Ballbach M, Kohlhaufl J, Fuchs KJ, Weber A, et al. The role of chitin, chitinases, and chitinase-like proteins in pediatric lung diseases. Mol Cell Pediatr. 2015; 2:3.
16. Brinchmann BC, Bayat M, Brogger T, Muttuvelu DV, Tjonneland A, Sigsgaard T. A possible role of chitin in the pathogenesis of asthma and allergy. Ann Agric Environ Med. 2011; 18:7–12.
17. Kojima S. Overview: from the horse experimentation by Prof. Akira Fujinami to paramyosin. Parasitol Int. 2004; 53:151–162.
18. Castellani L, Cohen C. Myosin rod phosphorylation and the catch state of molluscan muscles. Science. 1987; 235:334–337.
19. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013; 13:1543–1556.
20. Casset A, Mari A, Purohit A, Resch Y, Weghofer M, Ferrara R, et al. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol. 2012; 159:253–262.
21. Li N, Jiang YX, Diao JD, Zhao BB, Li CP. Effect of immunotherapy with recombinant allergen group 3 from dermatophagoides farinae in asthma mice. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2014; 32:280–284.